Strong Xywav Adoption With News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results
Continued Zepzelca Growth Across Second-Line SCLC Setting
Xywav in Idiopathic Hypersomnia Granted FDA Priority Review and an August 12, 2021, PDUFA Target Action Date
On Track to Close Acquisition of GW Pharmaceuticals plc in Early May, Creating an Innovative, High-Growth, Global Biopharma Leader
Secured $5.35 Billion Financing Including $1.5 Billion Senior Secured Notes in Connection with GW Acquisition
23% of Revenue from Recently Launched Products; Total Revenues Increased 14% to $607.6 Million Compared to First Quarter 2020
2021 Total Revenue Guidance Affirmed at $2.55 Billion to $2.70 Billion
DUBLIN, May 4, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2021 and affirmed financial guidance for 2021. ....

United States , Jacqueline Kirby , Pharma Mar , Andrean Flynn , Oxybate Xyrem , Robert Iannone , Erwinaze Erwinase , Epidiolex Epidyolex , Bruce Cozadd , Division Of Corporation , Corporate Affairs Government Relations , Oncology Center , American Academy Of Neurology Annual Meeting , Jazz Pharmaceuticals , Drug Administration , Gw Pharmaceuticals , Exchange Commission , Prnewswire Jazz Pharmaceuticals , Corporate Development , Wales Court , American Academy Of Neurology , Porton Biopharma , High Court , Strong Xywav Adoption With , Xywav Patients Exiting The First , Idiopathic Hypersomnia Granted ,